Hormonal
The effect of maternal hyperglycemia on childhood adiposity (overweight/obesity and sum of skinfold thickness) is sex-specific, being significant in girls but not in boys.
For girls exposed to maternal hyperglycemia in utero, parents should be particularly vigilant about monitoring weight and body composition, as they are at higher risk for childhood obesity and adiposity compared to boys. Regular check-ups focusing on growth charts and body fat percentage are recommended for these girls.
All three maternal glucose levels were also associated with increased adjusted ORs for childhood overweight or obesity and adiposity among girls, but not boys.
Why this rating
Consistent with the main study's rigorous design, though the sample size for sex-stratified analysis may be smaller.
Source
In Utero Exposure to Maternal Hyperglycemia Increases Childhood Cardiometabolic Risk in Offspring
Wing Hung Tam et al. · Diabetes Care · 2017
DOI 10.2337/dc16-2397
More from this paper
- In utero exposure to maternal hyperglycemia (gestational diabetes or elevated glucose levels) independently increases the risk of abnormal glucose tolerance, obesity, and higher blood pressure in offspring by age 7, independent of maternal pre-pregnancy BMI, birth weight, or childhood obesity.Good
- Maternal 1-hour glucose levels during pregnancy are specifically associated with an increased risk of childhood prehypertension or hypertension, independent of other glucose measures.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →